Seaport Therapeutics Advances Neuropsychiatric Pipeline with Strong Q1 2026 Progress
Event summary
- Seaport Therapeutics reported Q1 2026 revenue with $21.4M in R&D expenses and $6.1M in G&A expenses, resulting in a net loss of $25.4M.
- The company announced new multiple-ascending dose data for GlyphAgoTM, reinforcing its potential to avoid liver enzyme elevations.
- Enrollment in the Phase 2b BUOY-1 trial for GlyphAlloTM is on track, with topline data expected in the first half of 2027.
- Seaport completed an upsized IPO in May 2026, raising $260M in gross proceeds.
- Sharon Mates, Ph.D., former CEO of Intra-Cellular Therapies, joined Seaport's Board of Directors.
The big picture
Seaport Therapeutics is advancing its neuropsychiatric pipeline with promising clinical data for GlyphAlloTM and GlyphAgoTM. The company's recent IPO and strategic board appointment reflect its ambition to compete in the neuropsychiatric drug market. The success of its clinical trials will be pivotal in determining its long-term growth and market positioning.
What we're watching
- Clinical Milestones
- The pace at which Seaport Therapeutics can deliver topline data from its Phase 2b BUOY-1 trial for GlyphAlloTM and Phase 2a proof-of-pharmacology trial for GlyphAgoTM will be critical for its valuation.
- Regulatory Pathways
- Whether GlyphAlloTM and GlyphAgoTM can achieve registration-enabling status will determine the company's ability to bring these therapies to market.
- Financial Runway
- How Seaport Therapeutics manages its $260M IPO proceeds and extends its cash runway into 2029 will be key to sustaining its clinical development programs.
Related topics